NASDAQ$ZLAB
Zai Lab Limited-ADR · Q2 2022 earnings
Q2 2022 earnings · · Investor relations
Briefing
Announced second quarter 2022 financial results, highlighted by key pipeline milestones and continued revenue growth led by ZEJULA.
Zai Lab reported strong second-quarter results with continued revenue growth, particularly from ZEJULA. The company achieved key pipeline milestones, including the BLA acceptance of efgartigimod in China and positive topline results for the KarXT Phase 3 EMERGENT-2 trial. The company's cash position remains strong at $1.26 billion.
- BLA acceptance of efgartigimod by China’s NMPA.
- Positive topline results for the KarXT Phase 3 EMERGENT-2 trial.
- Continued revenue growth led by ZEJULA.
- Strong balance sheet with a cash position of $1.26 billion.
Headline financials
Revenue & EPS history
Zai Lab · Revenue · Quarterly
$48.2M
Revenue by segment
Zai Lab · $35.4M total across 2 segments · Q2 2022
- ZEJULA$34.1M+45.7%96.3%
- NUZYRA$1.3M—3.7%
Forward guidance
Zai Lab is on track to deliver its remaining 2022 corporate priorities, including an NDA submission to the NMPA for sulbactam-durlobactam, advancing ZL-1102 into full global development, and seeking NRDL inclusion for QINLOCK and NUZYRA.
Tailwinds
- NDA submission to the NMPA for sulbactam-durlobactam.
- Advancing ZL-1102 (anti-IL-17A Humabody®) into full global development.
- Seeking NRDL inclusion for QINLOCK.
- Seeking NRDL inclusion for NUZYRA.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q2 2022
-0.1%
Avg return
Earnings day
+0.3%
Avg return
5 days after
-0.5%
Avg return
30 days after
45%
13 / 29 earnings
Positive
+26.0%
Q1 2024
Best reaction
-11.2%
Q2 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -5.9% | -7.0% | -20.9% | |
| Q4 2025 | +1.7% | -8.6% | -7.2% | |
| Q3 2025 | -6.4% | -11.3% | -21.4% | |
| Q1 2025 | +2.5% | +0.9% | +34.4% | |
| Q4 2024 | -2.0% | -3.1% | +6.3% | |
| Q3 2024 | -3.7% | -13.0% | -14.1% | |
| Q2 2024 | -5.6% | -7.8% | +11.3% | |
| Q1 2024 | +26.0% | +29.0% | +19.9% | |
| Q4 2023 | -0.9% | +0.5% | -23.7% | |
| Q3 2023 | +7.4% | +0.9% | -1.5% | |
| Q2 2023 | -11.2% | -5.4% | +3.5% | |
| Q1 2023 | +1.4% | -9.3% | -24.2% | |
| Q4 2022 | -0.6% | +7.3% | -10.5% | |
| Q3 2022 | +1.9% | +23.9% | +18.7% | |
| Q2 2022 | -5.0% | -6.2% | -8.0% | |
| Q1 2022 | -2.1% | +30.0% | +5.6% | |
| Q4 2021 | -4.0% | -26.0% | -19.6% | |
| Q3 2021 | +0.7% | -2.3% | -22.3% | |
| Q2 2021 | +0.6% | +0.9% | +0.4% | |
| Q1 2021 | -5.1% | -3.3% | +8.3% | |
| Q4 2020 | +0.3% | -7.0% | -9.6% | |
| Q4 2019 | -1.4% | -2.7% | +17.0% | |
| Q1 2020 | -8.7% | +3.1% | +18.3% | |
| Q2 2019 | +4.3% | +4.1% | -4.0% | |
| Q1 2019 | +3.7% | +6.7% | -9.7% | |
| Q4 2018 | +10.4% | +10.4% | +1.6% | |
| Q3 2018 | +6.7% | +13.6% | +13.1% | |
| Q4 2017 | -5.3% | -8.8% | +22.8% | |
| Q3 2017 | -2.2% | -0.6% | +0.3% | |
| Q2 2017 | — | — | — | |
| Q1 2017 | — | — | — | |
| Q4 2016 | — | — | — | |
| Q3 2016 | — | — | — | |
| Q2 2016 | — | — | — | |
| Q1 2016 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro